| Autor: |
Ann-Kathrin Eisfeld, Ramiro Garzon, Albert de la Chapelle, Electra D. Paskett, John C. Byrd, Richard M. Stone, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Sophia E. Maharry, James S. Blachly, Isaiah Boateng, Shelley Orwick, Brian Giacopelli, Christopher Oakes, Alice S. Mims, Christopher J. Walker, Deedra Nicolet, James L. Fisher, Qiuhong Zhao, Krzysztof Mrózek, Jessica Kohlschmidt, Bhavana Bhatnagar |
| Rok vydání: |
2023 |
| Popis: |
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with cytogenetic and molecular factors and patient demographics (e.g., age and race). We compared survival of 25,523 non-Hispanic Black and White adults with AML using Surveillance Epidemiology and End Results (SEER) Program data and performed mutational profiling of 1,339 patients with AML treated on frontline Alliance for Clinical Trials in Oncology (Alliance) protocols. Black patients had shorter survival than White patients, both in SEER and in the setting of Alliance clinical trials. The disparity was especially pronounced in Black patients NPM1 and more IDH2 mutations in younger Black patients. Overall survival of younger Black patients was adversely affected by IDH2 mutations and FLT3-ITD, but, in contrast to White patients, was not improved by NPM1 mutations.Significance:We show that young Black patients have not benefited as much as White patients from recent progress in AML treatment in the United States. Our data suggest that both socioeconomic factors and differences in disease biology contribute to the survival disparity and need to be urgently addressed.See related commentary by Vyas, p. 540.This article is highlighted in the In This Issue feature, p. 521 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
